S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
NYSE:TFX

Teleflex (TFX) Stock Forecast, Price & News

$288.69
+2.35 (+0.82%)
(As of 05/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$282.87
$289.29
50-Day Range
$259.70
$354.83
52-Week Range
$256.77
$428.36
Volume
417,647 shs
Average Volume
360,151 shs
Market Capitalization
$13.54 billion
P/E Ratio
28.06
Dividend Yield
0.46%
Beta
1.13
30 days | 90 days | 365 days | Advanced Chart
Receive TFX News and Ratings via Email

Sign-up to receive the latest news and ratings for Teleflex and its competitors with MarketBeat's FREE daily newsletter.

Teleflex logo

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Headlines

Teleflex (NYSE:TFX) Cut to C+ at TheStreet
Teleflex (NYSE:TFX) Now Covered by Bank of America
Teleflex Incorporated (NYSE:TFX) Short Interest Update
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
87936910
Employees
14,000
Year Founded
1943

Sales & Book Value

Annual Sales
$2.81 billion
Cash Flow
$19.14 per share
Book Value
$80.93 per share

Profitability

Net Income
$485.37 million
Pretax Margin
20.07%

Debt

Price-To-Earnings

Miscellaneous

Free Float
46,300,000
Market Cap
$13.54 billion
Optionable
Optionable

Company Calendar

Ex-Dividend for 3/15 Dividend
3/04/2022
Dividend Payable
3/15/2022
Last Earnings
4/28/2022
Ex-Dividend for 6/15 Dividend
5/13/2022
Today
5/20/2022
Dividend Payable
6/15/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.40 out of 5 stars

Medical Sector

202nd out of 1,418 stocks

Surgical & Medical Instruments Industry

24th out of 137 stocks

Analyst Opinion: 3.3Community Rank: 4.1Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -













Teleflex (NYSE:TFX) Frequently Asked Questions

Is Teleflex a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last twelve months. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Teleflex stock.
View analyst ratings for Teleflex
or view top-rated stocks.

Are investors shorting Teleflex?

Teleflex saw a increase in short interest in April. As of April 15th, there was short interest totaling 598,800 shares, an increase of 23.5% from the March 31st total of 484,800 shares. Based on an average daily trading volume, of 319,000 shares, the short-interest ratio is currently 1.9 days.
View Teleflex's Short Interest
.

When is Teleflex's next earnings date?

Teleflex is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Teleflex
.

How were Teleflex's earnings last quarter?

Teleflex Incorporated (NYSE:TFX) issued its quarterly earnings results on Thursday, April, 28th. The medical technology company reported $2.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.72 by $0.16. The medical technology company earned $641.70 million during the quarter, compared to the consensus estimate of $631.89 million. Teleflex had a net margin of 17.31% and a trailing twelve-month return on equity of 17.24%. Teleflex's revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.87 EPS.
View Teleflex's earnings history
.

How often does Teleflex pay dividends? What is the dividend yield for Teleflex?

Teleflex declared a quarterly dividend on Monday, May 2nd. Stockholders of record on Monday, May 16th will be paid a dividend of $0.34 per share on Wednesday, June 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date is Friday, May 13th.
View Teleflex's dividend history
.

Is Teleflex a good dividend stock?

Teleflex pays an annual dividend of $1.36 per share and currently has a dividend yield of 0.46%. The dividend payout ratio of Teleflex is 13.22%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Teleflex will have a dividend payout ratio of 8.84% next year. This indicates that Teleflex will be able to sustain or increase its dividend.
View Teleflex's dividend history.

What guidance has Teleflex issued on next quarter's earnings?

Teleflex issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $13.70-$14.30 for the period, compared to the consensus earnings per share estimate of $13.89. The company issued revenue guidance of $2.87 billion-$2.92 billion, compared to the consensus revenue estimate of $2.90 billion.

What price target have analysts set for TFX?

12 brokerages have issued 12-month price targets for Teleflex's shares. Their forecasts range from $315.00 to $485.00. On average, they expect Teleflex's share price to reach $389.75 in the next twelve months. This suggests a possible upside of 35.0% from the stock's current price.
View analysts' price targets for Teleflex
or view top-rated stocks among Wall Street analysts.

Who are Teleflex's key executives?
Teleflex's management team includes the following people:
  • Mr. Liam J. Kelly, Chairman, Pres & CEO (Age 55, Pay $3.01M) (LinkedIn Profile)
  • Mr. Thomas E. Powell, Exec. VP & CFO (Age 60, Pay $1.44M)
  • Mr. Cameron P. Hicks, Corp. VP & Chief HR Officer (Age 57, Pay $771.45k) (LinkedIn Profile)
  • Mr. Jay White, Corp. VP & Pres of Global Commercial (Age 48, Pay $1.23M)
  • Mr. James P. Winters, Corp. VP, Manufacturing and Supply Chain
  • Mr. John R. Deren, Corp. VP & Chief Accounting Officer
  • Mr. Timothy F. Duffy, VP & Chief Information Officer
  • Mr. John Hsu C.F.A., VP of Investor Relations
  • Mr. Daniel V. Logue, Corp. VP, Gen. Counsel & Sec. (Age 48)
  • Mr. Howard Cyr, Corp. VP & Chief Compliance Officer
What is Liam Kelly's approval rating as Teleflex's CEO?

73 employees have rated Teleflex CEO Liam Kelly on Glassdoor.com. Liam Kelly has an approval rating of 86% among Teleflex's employees.

What other stocks do shareholders of Teleflex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teleflex investors own include NVIDIA (NVDA), AbbVie (ABBV), Johnson & Johnson (JNJ), Alibaba Group (BABA), Lam Research (LRCX), ServiceNow (NOW), QUALCOMM (QCOM), Advanced Micro Devices (AMD), Salesforce (CRM) and Cisco Systems (CSCO).

What is Teleflex's stock symbol?

Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."

Who are Teleflex's major shareholders?

Teleflex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.97%), BlackRock Inc. (9.25%), Wellington Management Group LLP (6.84%), State Street Corp (4.12%), American Century Companies Inc. (2.29%) and TD Asset Management Inc. (1.12%). Company insiders that own Teleflex stock include Andrew A Krakauer, Cameron P Hicks, Liam Kelly, Stephen K MD Klasko, Stephen K MD Klasko and Stuart A Randle.
View institutional ownership trends for Teleflex
.

Which institutional investors are selling Teleflex stock?

TFX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Hsbc Holdings PLC, Wellington Management Group LLP, Marathon Asset Management Ltd, BNP Paribas Arbitrage SA, CWM LLC, and Worldquant Millennium Advisors LLC. Company insiders that have sold Teleflex company stock in the last year include Cameron P Hicks, Liam Kelly, Stephen K MD Klasko, and Stuart A Randle.
View insider buying and selling activity for Teleflex
or view top insider-selling stocks.

Which institutional investors are buying Teleflex stock?

TFX stock was bought by a variety of institutional investors in the last quarter, including Eaton Vance Management, Ceredex Value Advisors LLC, Vanguard Group Inc., Sarasin & Partners LLP, Arrowstreet Capital Limited Partnership, Frontier Capital Management Co. LLC, Bridgewater Associates LP, and Goldman Sachs Group Inc..
View insider buying and selling activity for Teleflex
or or view top insider-buying stocks.

How do I buy shares of Teleflex?

Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teleflex's stock price today?

One share of TFX stock can currently be purchased for approximately $288.69.

How much money does Teleflex make?

Teleflex has a market capitalization of $13.54 billion and generates $2.81 billion in revenue each year. The medical technology company earns $485.37 million in net income (profit) each year or $10.289990 on an earnings per share basis.

How many employees does Teleflex have?

Teleflex employs 14,000 workers across the globe.

When was Teleflex founded?

Teleflex was founded in 1943.

What is Teleflex's official website?

The official website for Teleflex is www.teleflex.com.

How can I contact Teleflex?

Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at (610) 225-6800, via email at [email protected], or via fax at 215-553-5402.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.